Medicare Drug Price Negotiation Not A Major Threat To Pharma – Even If It Passes

The Medicare price negotiation provisions included in the Build Back Better bill would be manageable for biopharma if enacted and passage might even be a positive development because it would take drug pricing reform legislation off the table for a while, according to a group of biopharma analysts with Cowen.

As currently written, the negotiation process would apply to a limited number of high-cost drugs covered by Medicare Parts D ad B after their initial exclusivity period has expired